SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers
hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases …

Infection with SARS-CoV-2 results in clinical outcomes ranging from silent or benign
infection in most individuals to critical pneumonia and death in a few. Genetic studies in …

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with
APS-1 | Journal of Experimental Medicine | Rockefeller University Press Skip to Main Content …

Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19) …

We report the updated classification of Inborn Errors of Immunity/Primary
Immunodeficiencies, compiled by the International Union of Immunological Societies Expert …

Recessive or dominant inborn errors of type I interferon (IFN) immunity can underlie critical
COVID-19 pneumonia in unvaccinated adults. The risk of COVID-19 pneumonia in …

IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2
infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3 …

The vast interindividual clinical variability observed in any microbial infection—ranging from
silent infection to lethal disease—is increasingly being explained by human genetic and …

INTRODUCTION Clinical outcomes of human severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus …

Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19
pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring …